Nezam El-Tayebat Fact CheckA scientific assessment of the “نظام الطيبات” nutrition system
Choose country
Choose language: English

Potentially true Overinterpreted Certainty of evidence: low provisional C-ODD-12

Pioglitazone (Actos) raises bladder cancer risk by 63%.

In short: This claim is potentially true but overstated: a small increase in bladder cancer with long-term high-dose pioglitazone is plausible (pooled about 13%), while the 63% figure comes from one cohort and was not reproduced in other large cohorts.
Conclusion: Possibly true but overstated: a small bladder-cancer increase with long-term, high-dose pioglitazone is plausible (pooled about 13%), while the 63% figure comes from one cohort and was not reproduced in other large cohorts.
  1. Original statement
  2. Scientific assessment
  3. Scientific evidence in detail
  4. In plain language
  5. Studies on this claim
  6. Regional context
  7. What applies in my country?
  8. References

Original statement

أظهرت دراسة BMJ على 145,806 مريضاً أن بيوغليتازون (أكتوس) يرفع خطر سرطان المثانة 63%.

verbatim according to source. Translation by the project; the Arabic wording is authoritative.

Translation

Pioglitazone (Actos) raises bladder cancer risk by 63%.

Origin

Source status
Archive editors
Attribution
Archive editors (not Elawady)
Origin
https://eltayebat.com/rule/oral-diabetes-drugs/
Attribution uncertainty
Editorial narrative and study selection written by the archive operators.
Claimed health effect

Bladder cancer

Population concerned

Pioglitazone users

Geographic restriction by Elawady

none found

Scientific assessment

Potentially true – Some evidence points in favour of the statement, but it is not sufficient for a clear judgement.

Certainty of evidence: low – Further research is likely to change the assessment considerably.

1. What was claimed?

Pioglitazone raises bladder cancer by 63%.

2. What is demonstrably correct?

Tuccori et al.: HR 1.63 (1.22-2.19); 121.0 vs 88.9 per 100,000 person-years; duration and dose response; no association for rosiglitazone (A-ODD-03).

3. What is wrong or exaggerated?

'Raises' implies proven causation; the absolute excess is about 32 cases per 100,000 person-years. Pioglitazone also has potential benefits (not reviewed here).

4. What remains unclear?

Causality. Other large cohorts did not reproduce the 63% figure: Kaiser Permanente cohort of 193,099 aHR 1.06 (0.89-1.26) (I-ODD-123), four-country EU cohort aHR 0.99 (0.75-1.30) (I-ODD-125); a meta-analysis found a smaller pooled observational OR of 1.13 (1.03-1.25) with time and dose response (I-ODD-124).

5. Which studies support it?

A-ODD-03.

6. Which studies contradict it?

I-ODD-123, I-ODD-125 (no significant association); I-ODD-124 pooled OR 1.13 (smaller than 63%).

7. What applies to Germany and Europe?

EU labels contraindicate pioglitazone in current or past bladder cancer (not separately fetched).

8. What is known about Egypt?

Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.

9. What practical conclusion is appropriate?

A plausible rare risk that is part of prescribing decisions; blood in the urine on pioglitazone should be reported.

Assessment details

Rationale for certainty of evidence

Large population cohort with lag time, dose- and duration-response and a negative control (rosiglitazone) supports a real association; but it is observational, absolute risk difference is small (121 vs 89 per 100,000 person-years) and other large studies have produced mixed results (not reviewed in detail here).

Source quality

Archive editorial citing a population cohort.

Regional transferability

UK data; relevant to Europe.

Individual exceptions

History of bladder cancer or haematuria warrants avoiding pioglitazone.

Regional scope of the claim
general (biological/medical)
Last reviewed
26 October 2026 provisional

Scientific evidence in detail

Overinterpreted – A real finding exists, but the claim draws more from it than the data allow (e.g. association taken as cause, animal data applied to humans, small effect presented as large).

Research question: Does pioglitazone raise the risk of bladder cancer, and is a 63% increase representative?

Research question in detail (PECO)
Population
People with type 2 diabetes
Intervention or exposure
Pioglitazone
Comparison
Other glucose-lowering drugs / never-use
Geographic scope
universal biology
Outcomes
  • Bladder cancer

Study results as reported by the authors. Our assessment follows below.

What speaks for the claim?

What speaks against the claim?

What does the overall evidence say?

Editorial assessment based on the studies above – not itself a study result.

Which position is better supported?

A small association, mainly with long, high-dose use, is plausible (pooled OR 1.13; ADA notes association with higher cumulative exposure), but the 63% figure comes from one cohort and is not reproduced in other large cohorts.

Why some studies weigh more

Pooled estimates and large cohorts weigh more than a single cohort figure.

Is a causal relationship established? Possible, not established Dose-response supports, inconsistency weakens.

Remaining uncertainty

Causality and long-latency risk.

Justified conclusion

Potentially true for a small risk; 63% overstated as a general figure.

Why do studies seem to disagree?

Differences in follow-up length, latency windows, dose distributions and detection (urine testing) explain divergent cohort results.

Does this depend on the country?
General biological effects
Drug pharmacology and physiology are universal.
Eating habits
Prolonged fasting, Ramadan fasting and very-low-carbohydrate eating change the risk of hypoglycaemia and ketoacidosis with some drugs; relevant in Egypt and among Muslims in Europe.
Origin of the food
Not applicable.
Contaminants
Not applicable.
National production conditions
Not applicable (same active substances; generics widely used in Egypt).
Legal rules
Drug labels and warnings are set by FDA/EMA and national regulators; Egyptian labelling not reviewed.
Actual monitoring data
No Egypt-specific pharmacovigilance data were found for this outcome.

A regional difference that changes the conclusion is not supported by robust data.

Statistical re-check
  • Absolute excess – 32.1 per 100,000 PY = 1 extra case per about 3,100 PY. recalculated
  • CI symmetry and exclusion of 63% – aHR 1.06 (0.89-1.26): upper limit excludes 1.63. recalculated
Certainty of the overall evidence (GRADE, simplified)
Main outcome
Bladder cancer with pioglitazone
Starting level
low (observational studies)
Reasons for downgrading
  • inconsistency
Reasons for upgrading
  • dose-response (partial)
Result
low

Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.

Clinical guidelines and official statements checked
  • ADA: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (Diabetes Care 2026;49 Suppl 1) (2026) · Original publication
    Bladder cancer: do not use in active bladder cancer; use caution with prior history; association observed with higher cumulative exposure.
Search strategy

Documented literature searches for this review (search strings in the original database syntax).

DatabaseDateSearchLooking forHitsIncluded
PubMed26 October 2026pioglitazone[ti] AND "bladder cancer"[ti] AND (meta-analysis[pt] OR systematic review[pt] OR cohort[tiab])both directions22
ADA Standards of Care 2026, Section 9 (PubMed Central)26 October 2026Fetched https://pmc.ncbi.nlm.nih.gov/articles/PMC12690185/; bladder cancer statement. The diabetesjournals.org DOI landing pages returned HTTP 403; the identical article was read in PubMed Central.guidelines1

Open questions

Long-term follow-up beyond 10 years.

How deeply was this checked?

4 linked studies: 1 checked in full text (1 of them with a structured risk-of-bias assessment), 3 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.

Last scientific review: 26 October 2026

History of the verdict
  1. 25 October 2026 · Phase 1 · Initial assessment: Potentially true (low)
  2. 26 October 2026 · Phase 4 (systematic evidence review) · Re-examined with extended evidence; verdict unchanged: Potentially true (low)
    The previous review noted mixed results 'not reviewed in detail'; these are now added (I-ODD-123 to I-ODD-125). They confirm a small, inconsistent association; the verdict stays, bottom line sharpened about the 63% figure.
    New sources: I-ODD-123 I-ODD-124 I-ODD-125

In plain language

A large British study found that people using pioglitazone had more bladder cancer, especially after long use at high doses. The extra risk is about 3 cases per 10,000 people per year. This is taken into account by doctors when choosing the drug.

Studies on this claim

Studies supporting the claim (1)

  • Pioglitazone and bladder cancer

    Tuccori M et al.. BMJ 2016 · PMID 27029385 · DOI 10.1136/bmj.i1541
    Cohort studycited by the Tayebat archivefull text, structured risk-of-bias assessment

    Pioglitazone users had 63% more bladder cancer, about 3 extra cases per 10,000 people per year.

    Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Pioglitazone and bladder cancer

    How was the study done?

    Population-based cohort (CPRD), time-varying lagged exposure

    How many people, animals or samples were studied?

    145,806; New users of antidiabetic drugs

    What was actually found?

    HR 1.63 with dose/duration response.

    How large was the observed effect?

    HR 1.63 (1.22-2.19)

    What do the results mean in everyday life?

    Small absolute risk to consider.

    What are the study's limitations?

    Observational; only 54 bladder cancers in pioglitazone users; possible residual confounding or detection (more urine tests).

    What does it say about Elawady's specific claim?

    Supports C-ODD-12, C-ODD-05.

    Do the results apply to Germany and Europe?

    UK data.

    What can explicitly not be concluded from this study?

    Certain causation.

    Scientific details →

Studies contradicting or limiting the claim (2)

  • US cohort of 193,099: no significant bladder cancer increase with pioglitazone

    Lewis JD et al.. JAMA 2015 · PMID 26197187 · DOI 10.1001/jama.2015.7996
    Cohort studyindependent cross-checkabstract checked★ key study

    Adjusted HR 1.06 (0.89-1.26).

    aHR 1.06 (0.89-1.26).

    Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Test pioglitazone and cancer risk.

    How was the study done?

    Cohort and nested case-control.

    How many people, animals or samples were studied?

    193,099 people.

    What was actually found?

    No significant bladder cancer increase.

    How large was the observed effect?

    HR 1.06.

    What do the results mean in everyday life?

    The bladder cancer risk, if any, is small.

    What are the study's limitations?

    Observational.

    What does it say about Elawady's specific claim?

    Contradicts a firm 63% increase.

    Do the results apply to Germany and Europe?

    High.

    What can explicitly not be concluded from this study?

    No risk at all.

    Scientific details →

  • European data: no bladder cancer increase with pioglitazone over about 3 years

    Korhonen P et al.. BMJ 2016 · PMID 27530399 · DOI 10.1136/bmj.i3903
    Cohort studyindependent cross-checkabstract checked

    aHR 0.99 (0.75-1.30).

    aHR 0.99 (0.75-1.30); short follow-up; Takeda-funded.

    Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Test pioglitazone and bladder cancer in Europe.

    How was the study done?

    Propensity-matched cohort.

    How many people, animals or samples were studied?

    56,337 users.

    What was actually found?

    No association.

    How large was the observed effect?

    HR 0.99.

    What do the results mean in everyday life?

    Results differ between studies; any risk is small.

    What are the study's limitations?

    Short follow-up, industry funding.

    What does it say about Elawady's specific claim?

    Contradicts a general 63% increase.

    Do the results apply to Germany and Europe?

    Direct.

    What can explicitly not be concluded from this study?

    Long-term risk.

    Scientific details →

Studies with mixed or unclear results (1)

  • Pooled studies: pioglitazone linked to a small rise in bladder cancer

    Tang H et al.. Cancer Med 2018 · PMID 29476615 · DOI 10.1002/cam4.1354
    Meta-analysisindependent cross-checkabstract checked★ key study

    Observational OR 1.13 (1.03-1.25), higher with longer and higher-dose use.

    Pooled OR 1.13 with dose/time response; RCT OR 1.84 borderline.

    Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Pool pioglitazone-bladder cancer studies.

    How was the study done?

    Meta-analysis.

    How many people, animals or samples were studied?

    About 4.8 million people.

    What was actually found?

    Small association with dose and time response.

    How large was the observed effect?

    OR 1.13.

    What do the results mean in everyday life?

    A small possible risk, mainly with long high-dose use.

    What are the study's limitations?

    Mostly observational.

    What does it say about Elawady's specific claim?

    Supports a risk, not its 63% size.

    Do the results apply to Germany and Europe?

    High.

    What can explicitly not be concluded from this study?

    Causation.

    Scientific details →

Regional context

Germany / EU

EU labels contraindicate pioglitazone in current or past bladder cancer (not separately fetched).

Egypt

Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.

What applies in my country?

General scientific assessment

Potentially true Possibly true but overstated: a small bladder-cancer increase with long-term, high-dose pioglitazone is plausible (pooled about 13%), while the 63% figure comes from one cohort and was not reproduced in other large cohorts.

This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.

References

  1. Pioglitazone use and risk of bladder cancer: population based cohort study.. Tuccori M et al.. BMJ 2016 · PMID 27029385 · DOI 10.1136/bmj.i1541
  2. Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.. Lewis JD et al.. JAMA 2015 · PMID 26197187 · DOI 10.1001/jama.2015.7996
  3. Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries.. Korhonen P et al.. BMJ 2016 · PMID 27530399 · DOI 10.1136/bmj.i3903
  4. Pioglitazone and bladder cancer risk: a systematic review and meta-analysis.. Tang H et al.. Cancer Med 2018 · PMID 29476615 · DOI 10.1002/cam4.1354

← Back to overview